medigraphic.com
ISSN 0035-0052 (Impreso)

2008, Número 5

<< Anterior Siguiente >>

Rev Mex Pediatr 2008; 75 (5)


Transmisión materno-infantil del VIH/SIDA. La otra cara de la pandemia

Gorbea RMC

Idioma: Español
Referencias bibliográficas: 35
Paginas: 241-246
Archivo PDF: 89.24 Kb.


RESUMEN

Este artículo revisa la información reciente acerca de los factores de riesgo implicados en la transmisión vertical del VIH y sobre la exitosa aplicación de los antirretrovirales en la reducción de la transmisión perinatal del virus. La autora hace algunas reflexiones acerca de los niños que viven en el mundo del VIH/SIDA.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The working group of mother-to-child transmission of HIV. Rates of mother-to-child transmission of HIV in Africa, America and Europe: results from 13 perinatal studies. J Acquir Immune Def Syndr 1995; 8: 506-10.

  2. UNAIDS/WHO Working Group on Global HIV/AIDS and STD surveillance. Report on the Global HIV/AIDS Epidemic. Estimación en Diciembre 1999 Ginebra: World Health Organization; 1999. Disponible en http / www.Unaids.Org / unaids / document / epidemio / report99.htlm.

  3. Ramos JT, Ruiz-Contreras J, Bastero R, Barrio C, Moreno P, Delgado R et al. Estimación de la prevalencia de infección VIH en la embarazada, efectividad de la ZDV en la prevención de la transmisión vertical. Med Clin (Barc) 2000; 114: 245-9.

  4. Secretaría del Plan Nacional sobre el Sida, Registros autonómicos de casos de sida, Centro Nacional de Epidemiología. Vigilancia Epidemiológica del Sida en España. Registro Nacional. Informe Semestral n. 1, año 2000. Disponible en http/www.msc/es/sida/epidemiologia/actualizada/2000-.01.pdf

  5. Echeverría LJ, Landa MJJ, Iribarren LJA. Evolution of the strategies in the attention to gestant woman HIV (+) and its influence in vertical transmission. In: Final Program XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000; 107.

  6. Newell ML. Mechanisms and timing of mother-to-child transmission. AIDS 1998; 12: 831-7.

  7. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617-23, 134 Documentos de consenso de GESIDA sobre terapia antirretroviral y enfermedades asociadas al VIH (2000-2002).

  8. Mayaux MJ, Burgard M, Teglas JP, Cottalorda J, Krivine A, Simon F et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996; 275: 606-10.

  9. Mayaux MJ, Dussaix E, Isopet J, Rekacewicz C, Mandelbrot L, Vigneron NC et al. Maternal virus load during pregnancy and mother to child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. J Infect Dis 1997; 175: 172-5.

  10. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF et al. Perinatal HIV transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60.

  11. Mofenson LM, Wilfert CM. Pathogenesis and interruption of vertical transmission. In: Pizzo PA, Wilfert CM, editors. Pediatric AJDS. The challenge of HIV infection in infants, children and adolescents. Baltimore: Williams and Wilkins; 1998: 487-513.

  12. Boletín mensual SIDA/ETS, INDRE 1995; 9: 1: 2828.

  13. Gorbea RMC. Manejo integral del binomio madre-hijo con VIH/SIDA. 1ª ed. Ed. Manual Moderno. México 2003.

  14. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357-68.

  15. Ahmad N. The vertical transmission of human immunodeficiency virus type 1: molecular and biological properties of the virus. Crit Rev Clin Lab Sci 2005; 42: 1-34.

  16. Ahmad N. Molecular mechanisms of human immunodeficiency virus type 1 mother infant transmission. Adv Pharmacol 2000; 49: 387-416.

  17. Mok JQ, Giaquinto C, De Rossi A, Grosch-Worner I, Ades AE, Peckham CS. Infants born to mothers seropositive for human immunodeficiency virus. Preliminary findings from a multicentre European study. Lancet 1987; 1: 1164-8.

  18. Matala E, Hahn T, Yedavalli VR, Ahmad N. Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses 2001; 17: 1725-35.

  19. Hahn T, Ramakrishnan R, Ahmad N. Evaluation of genetic diversity of human immunodeficiency virus type 1 NEF gene associated with vertical transmission. J Biomed Sci 2003; 10: 436-50.

  20. Husain M, Hahn T, Yedavalli VR, Ahmad N. Characterization of HIV type 1 that sequences associated with perinatal transmission. AIDS Res Hum Retroviruses 2001; 17: 765-73.

  21. Zuber G, McDermott J, Karanjia S, Zhao W, Schmid MF, Barklis E. Assembly of retrovirus capsid- nucleocapsid proteins in the presence of membranes or RNA. J Virol 2000; 74: 7431-41.

  22. Heath MJ, Derebail SS, Gorelick RJ, DeStefano JJ. Differing roles of the N- and C-terminal zinc fingers in human immunodeficiency virus nucleocapsid protein-enhanced nucleic acid annealing. J Biol Chem 2003; 278: 30755-63.

  23. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251: 1-15.

  24. Krishnamoorthy G, Roques B, Darlix JL, Mely Y. DNA condensation by the nucleocapsid protein of HIV-1: a mechanism ensuring DNA protection. Nucleic Acids Res 2003; 31: 5425-32.

  25. Rice WG, Baker DC, Schaeffer CA, Graham L, Bu M, Terpening S, Clanton D, Schultz R, Bader JP, Buckheit RW Jr, Field L, Singh PK, Turpin JA. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997; 41: 419-25.

  26. Azoulay J, Clamme JP, Darlix JL, Roques BP, Mely Y. Destabilization of the HIV-1 complementary sequence of TAR by the nucleocapsid protein through activation of conformational fluctuations. J Mol Biol 2003; 326: 691-700.

  27. McGrath CF, Buckman JS, Gagliardi TD, Bosche WJ, Coren LV, Gorelick RJ. Human cellular nucleic acid-binding protein Zn2+ fingers support replication of human immunodeficiency virus type 1 when they are substituted in the nucleocapsid protein. J Virol 2003; 77: 8524-31.

  28. Heath MJ, Destefano JJ. A complementary single-stranded docking site is required for enhancement of strand exchange by human immunodeficiency virus nucleocapsid protein on substrates that model viral recombination. Biochemistry 2005; 44: 3915-25.

  29. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L. A leucine triplet repeat sequence (LXX) 4 in p6 gag is important for vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995; 69: 6873-9.

  30. Swofford DI. PAUP Phylogenetic analysis using palsimony and other methods, vol 400b2. Sunderland, MA: Sinauer associated; 1999.

  31. Posada DCK. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998; 14: 817-8.

  32. Hahn T, Matala E, Chappey C, Ahmad N. Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission. AIDS Res Hum Retroviruses 1999; 15: 875-88.

  33. Segal DJ, Goncalves J, Eberhardy S, Swan CH, Torbett BE, Li X, Barbas CF 3rd. Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004; 279: 14509-19.

  34. Kuhner MK, Yamato J, Felsenstein J. Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Genetics 1995; 140: 1421-30.

  35. Centers for Disease Control and Prevention Classification system for human immunodeficiency virus (HIV) in children under 13 years of age. MMWR 1987; 36: 225-36.




2020     |     www.medigraphic.com